Entresto
Entresto
$10,000.00
Entresto is a first-in-class angiotensin receptor/neprilysin inhibitor consisting of valsartan and sacubitril.
Author: Sita Indrakumar
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Entresto is a first-in-class angiotensin receptor/neprilysin inhibitor consisting of valsartan and sacubitril. Valsartan is an angiotensin receptor blocker (ARB) that competes with angiotensin II for binding to the AT1 receptor, while sacubitril is a prodrug that inhibits neprilysin, an enzyme responsible for the breakdown of several vasoactive peptides. The combined action of both molecules attenuates vasoconstriction and sodium retention, helping to improve the underlying pathology of chronic heart failure.
TABLE OF CONTENTS
4 Product Profiles
4 Entresto : Chronic heart failure (CHF)
LIST OF FIGURES
10 Figure 1: Entresto for chronic heart failure – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
17 Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Entresto drug profile
6 Table 2: Entresto Phase III data in chronic heart failure
8 Table 3: Ongoing pivotal trials for Entresto in chronic heart failure
18 Table 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the